Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 13/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 13/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927466 | 1.00 | MME (0.49) | MMEAGTR1ECE1AGTR2LTB4R2 | |
| SCHEMBL652748 | 0.95 | AGTR1 (0.48) | MMEAGTR1ECE1AGTR2LTB4R2 | |
| SCHEMBL651920 | 0.91 | MME (0.48) | MMEAGTR1ECE1AGTR2LTB4R2 | |
| SCHEMBL655018 | 0.86 | MME (0.47) | MMEAGTR1AGTR2LTB4R2 | |
| SCHEMBL651065 | 0.86 | AGTR1 (0.39) | MMEAGTR1ECE1AGTR2 | |
| SCHEMBL12532138 | 0.81 | MME (0.44) | MMEAGTR1ECE1 | |
| SCHEMBL2392191 | 0.80 | AGTR1 (0.48) | MMEAGTR1ECE1AGTR2LTB4R2 | |
| SCHEMBL1928982 | 0.79 | PPARG (0.49) | MMEAGTR1AGTR2PPARG | |
| SCHEMBL653074 | 0.79 | PPARG (0.49) | MMEAGTR1AGTR2PPARG | |
| SCHEMBL1258883 | 0.79 | AGTR1 (0.51) | MMEAGTR1ECE1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822522-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-02 | — | — | US | claimed |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | claimed |
| EP-2451782-B1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8350027-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8119634-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7956054-B2 | Dual-acting pyrazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259113-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 10/4885AGTR1 1/4885ECE1 15/4885 |
| US-20110009409-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 10/4885AGTR1 1/4885ECE1 15/4885 |
| US-20130245041-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MME 10/4885AGTR1 1/4885ECE1 15/4885 |
| US-20110275634-A1 | DUAL-ACTING PYRAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 13/4885AGTR1 1/4885ECE1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.